University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections
News Jul 21, 2009
Results from a study published by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads.
PCR-MS detected the presence of high-risk HPV in nearly half (46.7%) of women who tested negative by the Hybrid Capture 2 (HC2) test, which is standard of care in many countries. Approximately 9,000 American women are diagnosed with cervical cancer each year despite regular cervical screening.
The study, titled, Development and Evaluation of a PCR and Mass Spectroscopy-based (PCR-MS) Method for Quantitative, Type-specific Detection of Human Papillomavirus, will be published in the September 2009 edition of Journal of Virological Methods. The assay used in this study is exclusively licensed by SEQUENOM.
"We found that nearly half of the 75 women who had been called HPV-negative by the HC2 test had detectable levels of HPV DNA by the PCR-MS method," said Divya Patel, PhD, MPH, of the University of Michigan, one of the study investigators, and lead author of the recently published paper.
"More importantly, because the PCR-MS method also measures the quantity of HPV relative to the number of human cells in the sample, or 'viral load,' we determined that about 15% of these samples had HPV loads comparable to the HPV loads found in women called HPV-positive by the HC2 test. While further work to define clinically meaningful HPV detection thresholds is required, our results suggest that a type-specific, quantitative PCR-MS based test may be an important advance in the early detection of cervical cancer."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.